KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Share-based Compensation (2016 - 2025)

Regeneron Pharmaceuticals has reported Share-based Compensation over the past 17 years, most recently at $249.3 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $249.3 million for Q4 2025, down 18.1% from a year ago — trailing twelve months through Dec 2025 was $993.7 million (up 1.11% YoY), and the annual figure for FY2025 was $993.7 million, up 1.11%.
  • Share-based Compensation for Q4 2025 was $249.3 million at Regeneron Pharmaceuticals, up from $237.0 million in the prior quarter.
  • Over the last five years, Share-based Compensation for REGN hit a ceiling of $304.4 million in Q4 2024 and a floor of $130.9 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $224.2 million (2024), compared with a mean of $209.4 million.
  • Biggest five-year swings in Share-based Compensation: surged 55.06% in 2021 and later decreased 18.1% in 2025.
  • Regeneron Pharmaceuticals' Share-based Compensation stood at $188.4 million in 2021, then increased by 23.14% to $232.0 million in 2022, then grew by 3.62% to $240.4 million in 2023, then rose by 26.62% to $304.4 million in 2024, then decreased by 18.1% to $249.3 million in 2025.
  • The last three reported values for Share-based Compensation were $249.3 million (Q4 2025), $237.0 million (Q3 2025), and $251.7 million (Q2 2025) per Business Quant data.